Intimate Rose review

The FDA disclosure concerns the GLP-1 offer

FDA issued a September 9, 2025 warning letter to Intimate Rose about its compounded semaglutide and tirzepatide claims. The recipient's Kansas City-area address matches the address published by the company, and the letter identifies Intimate Rose's website. That attribution concerns the weight-loss drug line rather than its pelvic-floor products. A prospective patient should keep that distinction intact: the letter is material to this offer, while a familiar women's-health catalog should not be treated as either an exemption from the concern or proof that every unrelated product shares it.

The cited equivalence language has been replaced with a disclosure that the compounds are not generic versions and are not therapeutically equivalent to approved brands. That is useful product clarification, but a wording change does not by itself establish an FDA close-out or personal clinical suitability. Ask the treating professional to explain the actual preparation and rationale rather than transfer an approved brand's labeling or evidence to a compound because the active ingredient name is familiar. The letter and the current disclaimer answer related but different questions.

The current public price is a shared floor

Intimate Rose now advertises plans as low as $169 monthly without separate current public semaglutide and tirzepatide rates. Earlier $299 and $399 catalog amounts should not be presented as freshly confirmed standing offers, nor should the shared $169 floor become a guaranteed price for either molecule. Request the selected drug, formulation, dose, supply and complete payment schedule. A low program headline is useful for an initial inquiry but cannot establish the patient's continuing budget without the actual terms.

Older catalog information also included longer prepaid choices, which require their own current confirmation. A patient should not assume that the lowest annual equivalent, a former monthly quote and today's shared banner describe one interchangeable offer. Ask what is due immediately, which commitment applies and what charge follows. The public information leaves this unresolved, so the financial decision needs a written product-specific quote before a transfer or new treatment course is planned around it.

The storefront, practice and dispenser have separate roles

Plus EV Holdings, Inc. dba Intimate Rose operates the consumer brand, while the site says medical services come through OpenLoop Health and that Intimate Rose does not practice medicine or dispense medication. It names multiple pharmacy partners. Those disclosures can help identify a supply chain, but the patient should still obtain the actual medical practice and pharmacy assigned to the order. A partner list does not mean every preparation is identical or that every partner can serve every location.

Earlier fulfillment restrictions excluded Louisiana and additionally Alabama for tirzepatide; confirm current eligibility for the intended product and address. The published cancellation rule requires seventy-two hours before billing, with strict refund limits after charging or shipping and a separate medical-disqualification exception. Obtain the applicable agreement before paying. The adjacent pelvic-floor and menopause services do not establish a dedicated postpartum or breastfeeding pathway for GLP-1 care. Intimate Rose is most useful to assess through an identifiable prescription and full current quote, keeping its regulatory history, corrected product wording and actual cancellation conditions visible alongside the broader women's-health brand.